RU2277087C2 - Производные 4-фенилпиридина и лекарственное средство на их основе - Google Patents

Производные 4-фенилпиридина и лекарственное средство на их основе Download PDF

Info

Publication number
RU2277087C2
RU2277087C2 RU2003105805/04A RU2003105805A RU2277087C2 RU 2277087 C2 RU2277087 C2 RU 2277087C2 RU 2003105805/04 A RU2003105805/04 A RU 2003105805/04A RU 2003105805 A RU2003105805 A RU 2003105805A RU 2277087 C2 RU2277087 C2 RU 2277087C2
Authority
RU
Russia
Prior art keywords
methyl
bistrifluoromethylbenzyl
tolylnicotinamide
mmol
bistrifluoromethylphenyl
Prior art date
Application number
RU2003105805/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2003105805A (ru
Inventor
Тьерри ГОДЕЛЬ (CH)
Тьерри ГОДЕЛЬ
Торстен ХОФФМАНН (DE)
Торстен Хоффманн
Патрик ШНИДЕР (CH)
Патрик Шнидер
Хайнц ШТАДЛЕР (CH)
Хайнц Штадлер
Original Assignee
Ф.Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф.Хоффманн-Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг
Publication of RU2003105805A publication Critical patent/RU2003105805A/ru
Application granted granted Critical
Publication of RU2277087C2 publication Critical patent/RU2277087C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2003105805/04A 2000-08-08 2001-07-27 Производные 4-фенилпиридина и лекарственное средство на их основе RU2277087C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00117003.4 2000-08-08
EP00117003 2000-08-08

Publications (2)

Publication Number Publication Date
RU2003105805A RU2003105805A (ru) 2004-08-10
RU2277087C2 true RU2277087C2 (ru) 2006-05-27

Family

ID=8169466

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003105805/04A RU2277087C2 (ru) 2000-08-08 2001-07-27 Производные 4-фенилпиридина и лекарственное средство на их основе

Country Status (36)

Country Link
US (1) US6770637B2 (https=)
EP (1) EP1309559B1 (https=)
JP (1) JP4053877B2 (https=)
KR (1) KR100518201B1 (https=)
CN (1) CN1293056C (https=)
AR (1) AR030324A1 (https=)
AT (1) ATE328871T1 (https=)
AU (2) AU2002212118B2 (https=)
BR (1) BR0113173A (https=)
CA (1) CA2418868C (https=)
CZ (1) CZ2003684A3 (https=)
DE (1) DE60120419T2 (https=)
DK (1) DK1309559T3 (https=)
EC (1) ECSP034475A (https=)
ES (1) ES2264706T3 (https=)
GT (1) GT200100160A (https=)
HR (1) HRP20030055A2 (https=)
HU (1) HUP0301671A3 (https=)
IL (2) IL154079A0 (https=)
JO (1) JO2371B1 (https=)
MA (1) MA27680A1 (https=)
MX (1) MXPA03001143A (https=)
MY (1) MY128993A (https=)
NO (1) NO324841B1 (https=)
NZ (1) NZ523751A (https=)
PA (1) PA8524401A1 (https=)
PE (1) PE20020332A1 (https=)
PL (1) PL359849A1 (https=)
PT (1) PT1309559E (https=)
RU (1) RU2277087C2 (https=)
SI (1) SI1309559T1 (https=)
TW (1) TWI259180B (https=)
UY (1) UY26872A1 (https=)
WO (1) WO2002016324A1 (https=)
YU (1) YU8703A (https=)
ZA (1) ZA200300614B (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2481334C2 (ru) * 2007-08-10 2013-05-10 Альмираль, С.А. Производные азабифениламинобензойной кислоты в качестве ингибиторов dhodh
RU2544988C2 (ru) * 2009-12-23 2015-03-20 Галдерма Ресерч Энд Девелопмент Фенольные производные и их фармацевтическое или косметическое применение
RU2681316C2 (ru) * 2014-05-07 2019-03-06 Киссеи Фармасьютикал Ко., Лтд. Производные циклогексилпиридина
US12473260B2 (en) 2019-11-15 2025-11-18 KaNDy Therapeutics Limited Chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key intermediate of NT-814
RU2852587C1 (ru) * 2019-11-15 2025-12-10 Кэнди Терапьютикс Лимитед Новый химический способ получения 6-хлор-4-(4-фтор-2-метилфенил)пиридин-3-амина, ключевого промежуточного соединения для производства nt-814

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1103545E (pt) * 1999-11-29 2004-03-31 Hoffmann La Roche 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-totil-piridin-3-il)-isobutiramida
BR0313255A (pt) 2002-08-08 2005-07-12 Amgen Inc Composto, composição farmacêutica, uso de um composto e métodos de fabricar um medicamento e de preparar um composto
EP1688408A3 (en) * 2002-08-08 2007-08-22 Amgen, Inc Vanilloid receptor ligands and their use in treatments
WO2005000247A2 (en) * 2003-06-25 2005-01-06 Smithkline Beecham Corporation 4-carboxamido quinoline derivatives for use as nk-2 and nk-3
SI1643998T1 (sl) * 2003-07-03 2007-12-31 Hoffmann La Roche Dvojni nk1/nk3 antagonisti za zdravljenje shizofrenije
JP2007522233A (ja) 2004-02-11 2007-08-09 アムジエン・インコーポレーテツド バニロイド受容体リガンド及び治療におけるそれらの使用
MY139645A (en) 2004-02-11 2009-10-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
CN1984891B (zh) * 2004-07-06 2012-08-08 弗·哈夫曼-拉罗切有限公司 用作合成nk-1受体拮抗剂的中间体的甲酰胺吡啶衍生物的制备方法
KR100881240B1 (ko) * 2004-07-06 2009-02-05 에프. 호프만-라 로슈 아게 Ｎｋ-1 수용체 길항제의 합성에 있어서 중간체로서사용되는 카르복스아미드 피리딘 유도체의 제조 방법
CA2573198A1 (en) * 2004-07-06 2006-02-09 Xenon Pharmaceuticals Inc. Nicotinamide derivatives and their use as therapeutic agents
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
WO2006089311A1 (en) 2005-02-15 2006-08-24 Amgen Inc. Vanilloid receptor ligands and their use in treatments
JP2008531509A (ja) 2005-02-25 2008-08-14 エフ．ホフマン−ラ ロシュ アーゲー 医薬品成分の改良された分散性を有する錠剤
PT1868999E (pt) * 2005-04-06 2009-08-06 Hoffmann La Roche Derivados de piridino-3-carboxamida como agonistas inversos de cb1
EP2527337A1 (en) * 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
US7999113B2 (en) * 2005-08-11 2011-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP1928886B1 (en) 2005-09-09 2011-04-13 GlaxoSmithKline LLC Pyridine derivatives and their use in the treatment of psychotic disorders
CN102775396B (zh) 2005-11-08 2014-10-08 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的杂环调控剂
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
EP2674428B1 (en) 2006-04-07 2016-04-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
CN104447716A (zh) 2007-05-09 2015-03-25 沃泰克斯药物股份有限公司 Cftr调节剂
EP3683218B1 (en) 2007-12-07 2024-09-18 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
MX365732B (es) 2007-12-07 2019-06-12 Vertex Pharma Procesos para producir acidos cicloalquilcarboxamido-piridin benzoicos.
NZ720282A (en) 2008-02-28 2017-12-22 Vertex Pharma Heteroaryl derivatives as cftr modulators
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
UA107088C2 (xx) * 2009-09-11 2014-11-25 5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину
WO2011054773A1 (en) 2009-11-03 2011-05-12 Glaxosmithkline Llc Novel lactam compounds
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
MX2012011655A (es) 2010-04-07 2012-11-23 Vertex Pharma Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo [d][1-3]dioxol-5-il]ciclopropanocarboxamido)-3-metilpiridin-2-il) benzoico.
JP2013523833A (ja) 2010-04-07 2013-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与
MX353408B (es) 2010-04-22 2018-01-11 Vertex Pharma Proceso para producir compuestos de cicloalquilcarboxamido-indol.
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
WO2013049559A1 (en) * 2011-09-30 2013-04-04 Endo Pharmaceuticals Inc. Pyridine derivatives
WO2013070961A1 (en) 2011-11-08 2013-05-16 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
NZ727015A (en) 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
AR092857A1 (es) 2012-07-16 2015-05-06 Vertex Pharma Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas
RU2673084C2 (ru) * 2013-11-08 2018-11-22 Киссеи Фармасьютикал Ко., Лтд. Производное карбоксиметилпиперидина
AU2014349010C1 (en) 2013-11-12 2020-08-06 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
RU2744460C2 (ru) 2014-04-15 2021-03-09 Вертекс Фармасьютикалз Инкорпорейтед Фармацевтические композиции для лечения заболеваний, опосредованных муковисцидозным трансмембранным регулятором проводимости
RU2691136C2 (ru) 2014-11-18 2019-06-11 Вертекс Фармасьютикалз Инкорпорейтед Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии
WO2016149324A1 (en) * 2015-03-16 2016-09-22 Vanderbilt University Negative allosteric modulators of metabotropic glutamate receptor 2
WO2017112792A1 (en) 2015-12-22 2017-06-29 Takeda Pharmaceutical Company Limited Tripartite modulators of endosomal g protein-coupled receptors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0733632A1 (en) * 1995-03-24 1996-09-25 Takeda Chemical Industries, Ltd. Cyclic compounds, their production and use as tachykinin receptor antagonists
RU2077531C1 (ru) * 1990-05-31 1997-04-20 Пфайзер Инк. Способ получения замещенных (3-бензиламино)-2-фенилпиперидина, замещенные (3-бензиламино)-2-фенилпиридина и способ их получения
WO2000040237A1 (en) * 1999-01-07 2000-07-13 Warner-Lambert Company Antiviral method using mek inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56106286A (en) 1980-01-28 1981-08-24 Nippon Musical Instruments Mfg Electronic musical instrument
EP0103545A3 (en) 1982-09-13 1984-10-03 Arc Technologies Systems, Ltd. Electrode for arc furnaces
US4745123A (en) * 1986-02-18 1988-05-17 Warner-Lambert Company Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
CA2178219C (en) 1993-12-29 2005-03-22 Raymond Baker Substituted morpholine derivatives and their use as therapeutic agents
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
AR004735A1 (es) * 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
AU4885097A (en) * 1996-11-08 1998-06-03 Sankyo Company Limited Arylureas or arylmethylcarbamoyl derivatives
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
HRP20010603A2 (en) * 1999-02-24 2002-08-31 Hoffmann La Roche Phenyl-and pyridinyl derivatives
EP1394150B1 (en) * 1999-02-24 2011-01-19 F. Hoffmann-La Roche AG 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
WO2001028205A2 (en) * 1999-10-14 2001-04-19 Telefonaktiebolaget Lm Ericsson (Publ) System and method of retrieving voice mail messages in a telecommunications network
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
PT1103545E (pt) * 1999-11-29 2004-03-31 Hoffmann La Roche 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-totil-piridin-3-il)-isobutiramida

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2077531C1 (ru) * 1990-05-31 1997-04-20 Пфайзер Инк. Способ получения замещенных (3-бензиламино)-2-фенилпиперидина, замещенные (3-бензиламино)-2-фенилпиридина и способ их получения
EP0733632A1 (en) * 1995-03-24 1996-09-25 Takeda Chemical Industries, Ltd. Cyclic compounds, their production and use as tachykinin receptor antagonists
WO2000040237A1 (en) * 1999-01-07 2000-07-13 Warner-Lambert Company Antiviral method using mek inhibitors

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2481334C2 (ru) * 2007-08-10 2013-05-10 Альмираль, С.А. Производные азабифениламинобензойной кислоты в качестве ингибиторов dhodh
RU2544988C2 (ru) * 2009-12-23 2015-03-20 Галдерма Ресерч Энд Девелопмент Фенольные производные и их фармацевтическое или косметическое применение
RU2681316C2 (ru) * 2014-05-07 2019-03-06 Киссеи Фармасьютикал Ко., Лтд. Производные циклогексилпиридина
US12473260B2 (en) 2019-11-15 2025-11-18 KaNDy Therapeutics Limited Chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key intermediate of NT-814
RU2852587C1 (ru) * 2019-11-15 2025-12-10 Кэнди Терапьютикс Лимитед Новый химический способ получения 6-хлор-4-(4-фтор-2-метилфенил)пиридин-3-амина, ключевого промежуточного соединения для производства nt-814

Also Published As

Publication number Publication date
US20020040040A1 (en) 2002-04-04
HUP0301671A2 (hu) 2003-08-28
YU8703A (sh) 2006-05-25
PA8524401A1 (es) 2002-04-25
KR100518201B1 (ko) 2005-10-04
MA27680A1 (fr) 2006-01-02
GT200100160A (es) 2002-05-16
PT1309559E (pt) 2006-10-31
ZA200300614B (en) 2004-04-22
AU1211802A (en) 2002-03-04
NO20030632D0 (no) 2003-02-07
DK1309559T3 (da) 2006-10-02
CA2418868A1 (en) 2002-02-28
TWI259180B (en) 2006-08-01
NZ523751A (en) 2004-08-27
JO2371B1 (en) 2006-12-12
ES2264706T3 (es) 2007-01-16
CZ2003684A3 (cs) 2003-11-12
JP2004506718A (ja) 2004-03-04
AU2002212118B2 (en) 2005-12-15
SI1309559T1 (sl) 2006-10-31
ECSP034475A (es) 2003-03-31
ATE328871T1 (de) 2006-06-15
JP4053877B2 (ja) 2008-02-27
PL359849A1 (en) 2004-09-06
HRP20030055A2 (en) 2005-02-28
US6770637B2 (en) 2004-08-03
MY128993A (en) 2007-03-30
PE20020332A1 (es) 2002-05-10
CN1293056C (zh) 2007-01-03
WO2002016324A1 (en) 2002-02-28
EP1309559A1 (en) 2003-05-14
IL154079A0 (en) 2003-07-31
IL154079A (en) 2008-03-20
HUP0301671A3 (en) 2010-03-29
AR030324A1 (es) 2003-08-20
UY26872A1 (es) 2002-01-31
NO324841B1 (no) 2007-12-17
KR20030022370A (ko) 2003-03-15
CA2418868C (en) 2010-02-02
HK1076459A1 (en) 2006-01-20
DE60120419D1 (de) 2006-07-20
NO20030632L (no) 2003-02-07
MXPA03001143A (es) 2003-06-24
EP1309559B1 (en) 2006-06-07
BR0113173A (pt) 2003-06-24
CN1610670A (zh) 2005-04-27
DE60120419T2 (de) 2007-06-06

Similar Documents

Publication Publication Date Title
RU2277087C2 (ru) Производные 4-фенилпиридина и лекарственное средство на их основе
AU2002212118A1 (en) 4-phenyl-pyridine derivatives as Neurokinin-1 receptor antagonists
JP3399900B2 (ja) ４−フェニル−ピリジン誘導体
RU2266284C2 (ru) N-окиси производных 4-фенилпиридина, лекарственное средство, содержащее их
RU2236402C2 (ru) Производные 3-фенилпиридина и фармацевтическая композиция на их основе
RU2276139C2 (ru) Производные 4-фенилпиридина и лекарственное средство
JP2005531520A (ja) 置換２，３−ジフェニルピリジン類
AU2001282005A1 (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
CA2601935C (en) Nk1 antagonists
AU2001270619B2 (en) N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
AU2001270619A1 (en) N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20080728